EDIT vs NTLA
EDIT and NTLA side by side — valuation & fundamentals (public data).
Key statistics
| Metric | EDITEDITAS MEDICINE, INC. | NTLAINTELLIA THERAPEUTICS, INC. |
|---|---|---|
| Market cap | $402.38M | $1.66B |
| P/S | 9.9x | 25.0x |
| Revenue growth (YoY) | 25.4% | 16.9% |
| Earnings growth (YoY) | 32.5% | 20.5% |
| EBIT margin | -394.9% | -651.7% |
| ROE | -152.0% | -56.7% |
| 1y total return | -14.7% | -7.8% |
Figures from SEC filings · for reference only · not investment advice
Growth of $10,000: EDIT vs NTLA
| Metric | EDIT | NTLA |
|---|---|---|
| End value | $1.0K | $5.6K |
| Total return | -89.8% | -43.6% |
| CAGR | -19.8% | -5.4% |
| Volatility | 83.6% | 78.3% |
| Sharpe | 0.09 | 0.27 |
| Sortino | 0.14 | 0.39 |
| Max drawdown | -98.9% | -96.5% |
Based on 2600 common trading days, 2016-07-01 → 2026-11-03 · risk-free 4.21% (current short-Treasury, held constant)
A head-to-head total-return backtest over real split- and dividend-adjusted prices: how a one-time $10,000 investment in each stock, held to today, would have grown over their common window — including reinvested dividends. A disclosed historical statistic — NOT a prediction, a guarantee, or investment advice. Past performance does not predict future results.
Related comparisons
Delayed data · Public sources · For reference only · Not investment advice (this page declares no winner)